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Summary 
Adenosine is perhaps the most important and universal modulator in the brain. The current 
consensus is that it is primarily produced in the extracellular space from the breakdown of 
previously released ATP. It is also accepted that it can be released directly, as adenosine, during 
pathological events primarily by equilibrative transport. Nevertheless, there is a growing realization 
that adenosine can be rapidly released from the nervous system in a manner that is dependent upon 
the activity of neurons. We consider three competing classes of mechanism that could explain 
neuronal activity dependent adenosine release (exocytosis of ATP followed by extracellular 
conversion to adenosine; exocytotic release of an unspecified transmitter followed by direct non-
exocytotic adenosine release from an interposed cell; and direct exocytotic release of adenosine) 
and outline discriminatory experimental tests to decide between them. We review several examples 
of activity dependent adenosine release and explore their underlying mechanisms where these are 
known. We discuss the limits of current experimental techniques in definitively discriminating 
between the competing models of release, and identify key areas where technologies need to 
advance to enable definitive discriminatory tests. Nevertheless, within the current limits, we 
conclude that there is evidence for a mechanism that strongly resembles direct exocytosis of 
adenosine underlying at least some examples of neuronal activity dependent adenosine release. 
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Introduction 
Adenosine is one of the most important modulators in the brain. Originally discovered as a powerful 
vasodilator [21], adenosine acts as: an endogenous somnogen [3]; a retaliatory neuroprotective 
analyte during metabolic stress [16, 54]; a modulator of pain pathways [56]; a modulator of spinal 
motor output [7, 18]; and in many regions of the brain a depressor of synaptic transmission. 
 
Receptors 
Adenosine can act at 4 types of G-protein coupled receptors, respectively the A1, A2A, A2B and A3 
receptors (for comprehensive reviews see [26, 50]). A1 receptors are mostly inhibitory mainly 
coupling through the Gi/o type G proteins to inhibit adenylate cyclase. In some instances they can 
couple through Gq/11 to stimulate phospholipase C. The A2A and A2B receptors are broadly similar to 
each other with the A2A receptor being found in the central nervous system and the A2B receptor in 
peripheral tissues. The A2A receptor is largely excitatory coupling through Gs to stimulate adenylate 
cyclase. The A3 receptor is once again largely inhibitory and couples through Gi/o to inhibit 
adenylate cylase and stimulate phospholipase C. 
 
 
Mechanisms of adenosine production 
A common consensus implicit in the literature is that adenosine is not released via exocytosis. 
Instead there are two main pathways for its appearance and production in the extracellular space. 
Firstly it can arise from previously released ATP through the actions of several different enzyme 
families collectively called the ectonucleotidases, reviewed by [29, 53, 63-65]. These families 
comprise: the E-NTPDases (of which there are at least 4 members located in the plasma membrane 
and which have a variety of substrate specificities and convert ATP to either ADP or AMP); the E-
NPPases (of which there are 6 putative members, 3 of which have been shown to be capable of 
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converting ATP to AMP with one variant also able to produce adenosine from AMP); the ecto-
alkaline phosphatases (which have extremely broad substrate specificities) and the ecto-5’-
nucleotidase, which converts AMP to adenosine. There is no doubt that this is an important route of 
extracellular adenosine production. It has been well documented in for example spinal cord where 
ATP is produced during motor activity (see later). This route is also important for the adenosine 
tone that is present within the brain, which arises from prior release of ATP from astrocytes [49].  
 
However adenosine can also be released directly. This direct release seems to occur during 
pathologies such as oxygen-glucose deprivation (ischemia, [28]) and during hypercapnic acidosis in 
spinal cord [48]. The mechanism of release is uncertain, but is assumed to involve transporters. 
However there is conflicting evidence: for the most part the equilibrative transporters apparently act 
to remove adenosine from the extracellular space –their inhibition causes a rise in extracellular 
adenosine [19, 28]. This inward concentration gradient for adenosine may occur because adenosine 
kinase, a cytoplasmic enzyme, keeps the free intracellular adenosine concentration very low [5]. 
When this enzyme is inhibited, either pharmacologically [28, 60] or for example during 
hypercapnia in spinal cord [48], adenosine can be released via the equilibrative transporters. 
 
There is also growing evidence (reviewed below) that adenosine can be released, under non-
pathological conditions, by the activation of neurones by brief trains of action potentials.  This 
potentially important route for adenosine release links neural activity (action potentials) with a 
mechanism to feedback and inhibit the activated pathway (via A1 receptor activation) and the 
possibility of inhibiting neighbouring pathways, depending on the extent of adenosine diffusion. It 
is also possible that the released adenosine can produce changes in blood vessel diameter [41] and 
thus link neural activity with blood flow, although several other mediators released from astrocytes 
have also been proposed [44, 59, 67]. Although the exact mechanism of how the adenosine is 
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released remains unclear, there are hints that adenosine could be directly released by exocytosis. 
Below we outline some simple schemes that could account for activity-dependent adenosine release, 
discuss the way these schemes could be experimentally distinguished and summarise data from a 
number of different studies.  
 
Around 75% of energy expenditure in the brain is devoted to signalling [2]. One possible reason for 
activity-dependent adenosine release could be depletion of ATP levels during neural signalling. 
This depletion would however have to result in elevated levels of cytoplasmic adenosine to allow 
subsequent transport to the extracellular space. This may be significant during more global activity 
in the brain such as epileptic seizures, but seems an unlikely explanation for adenosine release that 
can be seen following brief activation of signalling (on the order of seconds) in small populations of 
neurons. Furthermore such a metabolic source of adenosine would be released in a Ca2+-
independent manner and by a transport dependent process. As there is evidence for transport-
independent and Ca2+-dependent mechanisms of adenosine release (see below), further mechanisms 
of activity-dependent release of adenosine must be considered. 
Activity-dependent adenosine release –possible mechanisms 
 
We therefore consider three further simple schemes to provide potential mechanisms for the 
activity-dependent release of adenosine Fig. (1).  All these schemes require exocytosis, as it is the 
simplest way of linking activity with release, and thus the release of adenosine in all cases will 
exhibit both calcium and action potential dependence. However only in case 3 will adenosine be 
packaged in vesicles and directly released by exocytosis. We shall consider these three schemes in 
detail and outline the critical experimental tests required to distinguish between them. 
 
Figure 1 inserted here 
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Scheme 1 (extracellular metabolism of ATP)   
Under this scheme ATP, released by exocytosis, is broken down in the extracellular space by 
ectoATPases and nucleotidases to produce adenosine. This scheme includes the direct exocytosis of 
ATP from neurones and also exocytosis of ATP from glia in response to a transmitter, for example  
glutamate, released from neurones. Rapid ATP release will be followed by the slower appearance of 
adenosine in the extracellular space. The reason for this slower dynamic of adenosine production is 
that ATP catabolism is a multienzyme process with the final step, conversion of AMP to adenosine, 
being subject to feed-forward inhibition by ATP and ADP [32]. 
 
A critical test of this scheme is to examine the sensitivity of adenosine production to blockers of the 
ectoATPases (such as ARL 67156) and the ecto- 5’-nucleotidase (such as α,β-methylene ADP). 
These should diminish the production of adenosine and hence reduce its effects; blockade of the 
ectoATPase may also enhance any direct effects of ATP mediated through P2 receptors. Ideally, 
direct measurement of extracellular ATP via luciferin-luciferase chemiluminescence (for example 
[46]) or with biosensors [37] and adenosine with biosensors [19, 36] or fast cyclic voltammetry [13, 
58] should be attempted.  With these techniques, it may be possible to directly demonstrate the 
characteristic delays in adenosine production with respect to neural activity that betokens 
extracellular conversion of ATP and the intervening metabolites [19, 20, 32]. 
 
Thus the absence of an effect of blockade of extracellular ATP catabolism on adenosine production 
and the appearance of adenosine in the absence of any ATP release would eliminate this scheme 
from consideration, subject to the caveats outlined below. 
 
Scheme 2 (interposed transmitter) 
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Under the second scheme, an unspecified neurotransmitter would be released (by exocytosis) to 
activate an interposed cell (either a neuron or astrocyte) to produce adenosine release (by some 
currently unclear mechanism). 
 
The discriminatory test would be to block the receptors of the interposed transmitter (with selective 
antagonists) –these should diminish adenosine release. The difficulty is that the identity of the 
interposed transmitter will be unknown; therefore even use of an exhaustive battery of antagonists 
may not be conclusive if these all provide negative results.  There are many examples where 
activation of glutamate receptors has been shown to release adenosine (for review see [35]). 
Determining whether adenosine release is sensitive to glutamate receptor blockade is thus an 
important test, however other types of transmitter should also be examined including the 
cannabinoids, which can induce changes in intracellular Ca2+ in neurons and astrocytes [22]. If the 
interposed cell were to be an astrocyte, then it is vital to directly image astrocytic signalling (via 
intracellular Ca2+) to demonstrate the efficacy or otherwise of the antagonist regimen in preventing 
astrocytic activation. 
 
An alternative and more general way of testing this scheme is to try and inactivate the putative 
interposed cell. If this is a neuron, then massive activation of GABAA receptors will shunt the 
membrane and hence the excitatory effects of the putative interposed transmitter, without greatly 
diminishing release of the transmitter itself. A difficulty arises if the interposed cell is an astrocyte 
as these may not possess GABAA receptors. Some authors have used fluorocitrate and fluoroacetate 
to alter astrocytic function [39]. We have concerns as to the specificity of such treatments and 
whether they are adequate tests of astrocytic involvement. Other ways to test the involvement of 
interposed astrocytes that may be of utility would be their selective loading with Ca2+ chelators 
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(possible in brain slices derived from young rodents [17]) or the use of genetically altered mice 
where astrocytic signalling has been selectively disrupted [49]. 
 
However we conclude that is very hard to completely eliminate this scheme as an explanation of 
adenosine release –at any point a positive result will demonstrate that this scheme applies, e.g. 
sensitivity of adenosine release to glutamate receptor antagonism, but a series of negative results to 
all of these tests cannot completely exclude this explanation either. 
 
 
Scheme 3 (direct exocytosis of adenosine) 
The final mechanism is the direct release of adenosine by exocytosis. This implies the loading of 
adenosine into synaptic vesicles –perhaps hard to achieve if cytoplasmic adenosine levels are very 
low, which can be the case for cells in which adenosine kinase is strongly expressed. However a 
recent report suggests that adenosine kinase is largely absent from hippocampal neurons of adult rat 
supporting the plausibility of vesicular loading [57]. 
 
Under this scheme it is necessary to show the release of adenosine in the absence of the release of 
ATP as well as insensitivity to blockers of ATP catabolism. However conclusive demonstration of 
adenosine exocytosis is difficult. One obvious reason for this is that adenosine does not act through 
a ligand-gated channel thus the possibility, which would definitively and easily demonstrate this 
scheme, of observing adenosinergic miniature postsynaptic currents or potentials, does not exist. 
 
An excellent, but difficult, test is to block exocytosis from the cell type hypothesized to release 
adenosine –this may be possible with genetically altered rodent models (for example [62]), however 
these data would not necessarily exclude involvement of an interposed cell (scheme 2). 
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Demonstration of the presence of adenosine in synaptic vesicles would provide supporting evidence 
for this hypothesis. Ultimately however, definitive evidence will require demonstration of 
adenosine release via exocytosis from isolated cells (either acutely or in culture). Further 
developments in adenosine sensing technologies may make this test possible. 
 
Examples of activity dependent adenosine release 
There are a number of brain regions where activity-dependent adenosine release has been described. 
We will examine them and discuss the evidence for which scheme may underlie the release. 
 
Xenopus spinal motor pattern generation 
ATP and adenosine modulate spinal motor pattern generation in Xenopus embryos. ATP is 
excitatory acting through P2Y receptors to inhibit voltage gated K+ channels [9, 18]. Adenosine 
depresses motor activity, and acts by inhibiting voltage-gated Ca2+ channels [8, 18]. The dynamic 
balance between these modulators changes with time during swimming activity and results in a 
gradual slowing and spontaneous termination of the motor pattern. This system involves the release 
and production of both ATP and adenosine –their postsynaptic effects can be demonstrated via the 
use of antagonists. Direct demonstration of ATP release from isolated neurons [10], and from the 
spinal cord during locomotion has been achieved [37]. Adenosine production during swimming has 
also been demonstrated [19, 36]. This has the predicted slow dynamic arising from extracellular 
catabolism of ATP [19, 20, 36]. Thus this is a clear example of adenosine release arising via scheme 
1. 
 
Hippocampal CA1 synapses 
Glutamatergic synapses onto CA1 pyramidal neurones are modulated by the activation of A1 
receptors leading to presynaptic inhibition [24, 55]. Mitchell et al (1993) [42] provided the first 
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evidence for a form of activity-dependent adenosine release at these synapses. They showed that the 
activation of an excitatory pathway onto CA1 neurones leads to the transient depression of fEPSPs 
evoked in another independent pathway Fig. (2). This inhibition was produced by the release of 
adenosine (presumably from a component within or activated by the stimulated pathway) and the 
subsequent activation of presynaptic A1 receptors (as the inhibition could be blocked by the 
adenosine receptor antagonist theophylline). Although the depression was seen with a single 
stimulus it was much more pronounced with a train of stimuli (16-23, at 100 Hz) presumably as 
more adenosine is released [42]. The degree of inhibition was also increased if the extracellular 
breakdown of adenosine was reduced with an adenosine deaminase inhibitor (EHNA) and thus 
presumably greater concentrations of adenosine can diffuse to the depressed pathway [42]. Similar 
results have also been observed using organotypic slices, where the short-term depression of a 
single CA1 pathway (with a 10 Hz, 5 s stimulation) was partly reversed by blocking A1 receptors 
[6].  Thus the adenosine released can inhibit both the stimulated pathway and diffuse to inhibit 
neighbouring pathways. Functionally, adenosine release occurring during high frequency 
stimulation can block the consolidation of LTP [1, 14]. Activity-dependent adenosine release is also 
seen during seizures generated in the hippocampus and acts to terminate the seizures [25]. 
 
Figure 2 inserted here 
 
What is the mechanism of this activity-dependent adenosine release? Addition of a 5’-
ectonucleotidase inhibitor (200-500 µM α,β methylene-ADP) had no effect on the degree of 
synaptic depression [6, 42] suggesting that the adenosine does not arise from the extracellular 
metabolism of ATP (eliminating scheme 1). The adenosine release persisted in 10 µM dipyridamole 
[6] suggesting that it may not arise from cytoplasmic translocation via a carrier protein, nevertheless 
this possibility is not completely excluded as a dipyridamole-insensitive carrier could still be 
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involved.  There is currently no data on whether the release of an interposed transmitter is required 
for adenosine release or indeed whether the adenosine release involves exocytosis.   However, 
Manzoni et al (1994) [38] have shown that NMDA receptor activation causes the release of 
adenosine and subsequent inhibition of CA1 synapses via A1 receptor activation.  This adenosine 
release persisted in the presence of α,β methylene ADP (500 µM) and thus does not appear to 
involve the breakdown of extracellular ATP.  Slice superfusion experiments suggest that this 
adenosine release is Ca2+ dependent [15] and thus may involve exocytosis. The obvious question is: 
does activity-dependent release of adenosine produced by synaptic stimulation require NMDA 
receptor activation (implying a scheme 2 type mechanism)? This currently remains unknown but 
would be relatively easy to answer by stimulating CA1 synapses with trains, with and without an 
NMDA receptor antagonist.    
 
What is the source of the adenosine? Brundege and Dunwiddie (1996) [11] showed that loading 
CA1 pyramidal neurones with adenosine (via a patch pipette) led to adenosine release and the 
presynaptic inhibition of glutamatergic synaptic transmission on to the cell. However loading the 
neurones with enzyme inhibitors and nucleotides had no effect on the degree of synaptic 
transmission suggesting that pyramidal cells do not readily form adenosine from endogenous 
sources [12]. Manzoni et al (1994) [38] suggested that the NMDA receptor mediated adenosine 
release could be via inhibitory interneurones as it was reduced by enkephalin, which selectively 
inhibits interneurones.  
 
The Calyx of Held 
The Calyx of Held is a giant nerve terminal in the auditory brainstem forming an axo-somatic 
glutamatergic synapse onto a principal cell in the medial nucleus of the trapezoid body (MNTB). 
Transmission at this synapse is depressed by the activation of presynaptic adenosine A1 receptors [4] 
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an effect that declines during postnatal development [33]. Kimura et al (2003) [33] showed, with an 
A1 receptor antagonist (8 CPT), that there is no tone of adenosine continually activating the A1 
receptors.  However during high frequency trains (10 Hz), blocking A1 receptors relieved a 
proportion of the synaptic depression, suggesting that adenosine release occurred during the train 
Fig. (3) [33]. By comparing the degree of inhibition relieved by 8 CPT (~13 %) and the adenosine 
concentration-response curve it was possible to estimate the concentration of adenosine released, 
which reached ~ 5 µM [33].   
 
Figure 3 inserted here 
 
What is the mechanism for this activity-dependent adenosine release? Blocking extracellular ATP 
metabolism (with the ectoATPase inhibitor ARL 67156, 50 µM) had no effect suggesting the 
adenosine does not arise from the extracellular breakdown of ATP (eliminating scheme 1, [61]). 
This was supported by the inability of the luciferin-luciferase assay to detect any ATP release 
following a 200 Hz train [61]. However there is currently no information on whether the adenosine 
release requires exocytosis and whether the release of an interposed transmitter is required.  The 
most likely source of the adenosine is the excitatory terminals (which release glutamate and express 
the A1 receptors) and thus the adenosine acts to depress excitatory synaptic transmission (and 
presumably its own release) via autoreceptors [61].  
 
Parallel fibre-Purkinje cell synapses in the cerebellum    
Glutamatergic parallel fibre to Purkinje cell synapses are inhibited by the activation of presynaptic 
adenosine A1 receptors [34, 52]. Adenosine biosensors [36] placed on the surface of the molecular 
layer of transverse slices (above the parallel fibre tracts) can detect adenosine release following 
trains (5-80 Hz) of stimuli Fig. (4) [60]. The amount of adenosine released was increased by 
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increasing the number of stimuli and by the higher frequencies of stimulation. Sufficient adenosine 
was released to inhibit parallel fibre-Purkinje cell synaptic transmission, an effect blocked by A1 
receptor antagonists [60]. 
 
What is the mechanism of adenosine release? As with the hippocampus and Calyx of Held, the 
amount of adenosine released was not reduced by blocking extracellular ATP breakdown (with 
Evans Blue, ARL 67156 or α, β-methylene ADP at 100 µM) [60]. Furthermore ATP biosensors 
(detection limit ~ 60 nM, [37]) placed either in the slice or in the same position as the adenosine 
biosensor did not detect ATP release following trains of stimuli [60]. Release of ATP by local 
electroporation [c.f. 30] led to rapid adenosine production (via extracellular metabolism) but the 
proportion of ATP broken down to adenosine was relatively small (~20 %) suggesting that 
complete and rapid ATP breakdown was extremely unlikely [60]. Thus it appears that the source of 
adenosine is not extracellular ATP eliminating scheme 1. The adenosine release was reversibly 
blocked by tetrodotoxin (action potential dependent) and was also Ca2+ dependent [60].  Thus the 
release mechanism appears to involve exocytosis and thus probably occurs either by scheme 2 
(interposed transmitter release) or by scheme 3 (direct release of adenosine by exocytosis).  
Adenosine release was not reduced by blocking a number of transmitter receptors (including 
glutamate, noradrenaline and 5 HT) and was not reduced by shunting neurones and glia by 
activating GABAA receptors with muscimol [60]. Furthermore release was not reduced by blocking 
adenosine transport via ENT1 and ENT2 (with NBTI/dipyridamole). Thus it appears unlikely that 
the adenosine release occurs by scheme 2. The simplest explanation is that the release mechanism is 
direct exocytosis of adenosine. 
 
Figure 4 inserted here 
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What is the source of the released adenosine? The position of the stimulating and recording 
electrodes, along a beam of parallel fibres, are ideal to stimulate and record release from parallel 
fibres. Furthermore, activation of presynaptic receptors on parallel fibre terminals (GABAB mGluR4 
and A1 receptors) causes a reversible reduction in adenosine release [60]. The restricted location of 
mGluR4 receptors in the cerebellum (only present on parallel fibre terminals [40]), strongly 
suggests that adenosine release occurs from the terminals of parallel fibres. Block of A1 receptors 
(with 8 CPT) markedly increased the amount of adenosine released suggesting that the A1 receptor 
acts as an autoreceptor, controlling the amount of adenosine and glutamate released [60].    
 
Insert table here 
 
Other Synapses 
In the rat hypothalamic supraoptic nucleus, blocking A1 receptors had no effect at a low frequency 
synaptic stimulation (0.05-0.5 Hz) but at 1 Hz, the time-dependent depression of inhibitory and 
excitatory transmission was prevented by A1 receptor block [47].  Thus it appears that activity-
dependent adenosine release occurs during trains of activity in a similar fashion to the other 
synapses.   
 
Limitations of studies 
There are at least three experimental limitations that prevent the full elucidation of the mechanisms 
underlying activity-dependent adenosine release: 
 
Low efficacy of the inhibitors of extracellular ATP catabolism.  
Critical for the evaluation of scheme 1, is to test whether adenosine arises from the extracellular 
breakdown of ATP by using inhibitors of the ectoATPases  and ecto-5’-nucleotidase.  This is fine if 
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the inhibitor has a positive effect (reducing the amount of adenosine released). However a lack of 
effect, may be a false negative as the agents may not have effectively blocked the breakdown of 
ATP. This is plausible, as the widely used NTPDase inhibitor, ARL 67156, has relatively low 
efficacy and is a competitive antagonist. High concentrations of ATP will overcome its relatively 
weak blocking action [28, 43, 60].  In cerebellum, the 5’-nucleotidase inhibitor α,β-methylene ADP 
appears the most effective agent in preventing the production of adenosine [60] but its action is 
competitive and thus will be overcome by high levels of substrate. By contrast α,β-methylene ADP 
is ineffective at blocking the ecto-5’-nucleotidase in Xenopus and acts instead as an agonist at a 
P2Y1 receptor [9]. Indeed several P2 receptor antagonists such as suramin, PPADS, NF449, NF279 
and RB-2 are effective blockers of at least some E-NTPDases [31, 45, 67], complicating 
interpretations over the use of these compounds. 
 
There are convenient methods to analyze the extracellular catabolism of ATP in situ and in brain 
slices [9, 28, 60]. These allow determination of the efficacy of putative inhibitors of the 
ectoATPases and ecto-5’-nucleotidase and we strongly recommend their use to give greater 
credibility to the interpretations resulting from the use of these compounds. 
 
Many studies only measure adenosine release indirectly via the inhibition of synaptic transmission 
by the activation of presynaptic A1 receptor.  Because the A1 receptors have a very high affinity for 
adenosine (EC50 600-750 nM for depressing CA1 EPSPs, [23]), it is probable that only a small 
proportion of the extracellular ATP has to be broken down to produce significant A1 receptor 
activation.  Thus if the inhibitors are only partially effective, enough adenosine may still be 
produced to cause synaptic inhibition. Although this problem can be reduced by combining the 
inhibition of ATP breakdown with other methods such as biosensors [60] and luciferin-luciferase 
[61] to detect ATP release, there always remains the doubt that if no ATP is detected it is because of 
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extremely rapid breakdown that has not been prevented by the inhibitor.  Thus future studies require 
either the development of new more effective NTPDase inhibitors (for example see [43]) or the use 
of transgenic technology to prevent extracellular ATP breakdown. 
  
Indirect measurements of adenosine release  
Most of the studies of activity-dependent adenosine release, indirectly measure the adenosine 
released by the activation of A1 receptors and the subsequent inhibition of synaptic transmission.  
There are two major problems with this method: firstly any procedure that modulates adenosine 
release but also changes synaptic transmission cannot be examined. For example procedures such as 
removing extracellular Ca2+ or blocking action potentials (with tetrodotoxin) cannot be used as they 
will also block synaptic transmission and thus the influence of adenosine on transmission can no 
longer be measured. Secondly, the quantification of the amount of adenosine is difficult as the 
degree of synaptic inhibition is not always linearly related to the amount of adenosine present (at 
the bottom of the concentration curve and at the top where receptors are saturated). This problem 
can be avoided by combining measurements of synaptic inhibition with a direct real-time measure 
of adenosine release using for example a biosensor [27, 60]. 
 
Exclusion of an interposed transmitter 
It is difficult to distinguish whether adenosine is directly released by exocytosis or whether there is 
an interposed transmitter (schemes 2 and 3).  This is because there are a large number of possible 
transmitter candidates and it is difficult to test them all. Wall & Dale (2007) [60] used the shunting 
of neurones and glia with the GABAA receptor agonist muscimol to exclude release from interposed 
neurones and glia.  Although Purkinje cells were effectively shunted, the effects on glia remain 
unclear although they do express GABAA receptors [51]. Future strategies could include the use of 
transgenic mice, where exocytosis from glia is blocked (dominant-negative SNARE, [49]) or 
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transmission at specific synapses is blocked (for example by selective tetanus toxin expression, [62]) 
or the measuring of adenosine release from cultures of specific cell types. 
   
Conclusions 
There is growing evidence that activity-dependent adenosine release occurs in several different 
brain areas and thus is perhaps a common feature of many central neural circuits. In all of the 
reports, a train of electrical activity (usually in glutamatergic neurones), releases adenosine which 
feeds back to inhibit transmitter release in the stimulated pathway. In many cases, although the 
adenosine does not arise from extracellular ATP breakdown (but see the caveats above) it is still 
unclear where and how the adenosine is released.  In the cerebellum, where the story is most 
complete [58], the simplest mechanism that accounts its release is the direct exocytosis of adenosine 
from parallel fibres, although future experiments are required to prove this definitively. The use of 
biosensors in the cerebellum has allowed much greater insight into the properties of adenosine 
release compared to studies which only monitored adenosine release indirectly (via synaptic 
inhibition). For example, cerebellar adenosine release is modulated by the activation of presynaptic 
receptors such as GABAB and mGluR4 and adenosine itself can feedback to inhibit its own release 
(via A1 receptor activation).  Thus the adenosine release appears more like conventional transmitter 
release than perhaps expected and in many ways can be treated as a slow postsynaptic potential. 
Furthermore, the complexity of adenosinergic signalling is enhanced, as the amount of adenosine 
released will not only depend on the stimulus but also can be potentially modulated by several 
feedback mechanisms. Thus the full understanding of how adenosine is released and its effects on 
neural circuit behaviour will require the combination of electrophysiology, biosensor technology, 
computational studies and the development of new tools, for example effective NTPDase blockers 
and transgenic technology.  
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Figure 1. Possible mechanisms for activity-dependent adenosine release.  
1) ATP is released by exocytosis (either from a neuron or glial cell) and subsequently metabolised 
in the extracellular space to produce adenosine. 2) An unspecified interposed transmitter (?) is 
released by exocytosis to act on a downstream cell causing the release of adenosine by an unknown 
mechanism (?). 3) Direct exocytotic release of vesicular adenosine. 
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Figure 2. Transient inhibition of hippocampal CA1 field EPSPs by conditioning stimulation. 
Field excitatory postsynaptic potentials (fEPSPs) were measured in the apical dendrites of CA1 and 
were stimulated by an electrode placed in the stratum radiatum of CA2.  A conditioning electrode 
was placed in the stratum radiatum of CA1 near the subiculum.  A) Amplitudes of fEPSPs evoked 
every 30 seconds. At 5 minute intervals, a conditioning train consisting of 5 pulses was applied 
ending 200 ms prior to the fEPSP.  B) fEPSPs from the shaded area of A.  Responses are shown to 
test stimulation alone (T) and 200 msec after the conditioning pulses (C-P T). fEPSPs preceded by 
the conditioning pulses were reduced 15-20 % relative to the baseline. Taken with permission from 
[42]. 
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Figure 3. Presynaptic inhibition by endogenous adenosine is increased during high frequency 
stimulation at the Calyx of Held 
Excitatory postsynaptic currents (EPSCs) were recorded from MNTB principal neurons in P5-7 rats 
in response to stimulation of input fibres. A) Averaged EPSCs during a train of 30 stimuli at 10 Hz. 
The first EPSC (I0) and the 27th-30th EPSCs, before (black) and during (red) application of CPT 
(0.5 µM), are shown (superimposed). B) Synaptic depression during 10 Hz stimulation. EPSCs 
during a train are normalized in amplitude to the first EPSC. Mean amplitudes and S.E.M.s of EPSCs 
(from five cells with significant increase in mean amplitude of 20th- 30th EPSCs (Iss) after CPT 
application, D) during 10 Hz stimulation are plotted, before ( ) and during ( ) CPT application. C, 
Time plot of I0 and Iss in a cell. Bath application of CPT (bar) increased Iss with no effect on I0. 
Mean amplitude of Iss before CPT application is indicated by a dashed line. D) mean amplitudes of 
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Iss before and after application of CPT in seven cells. Difference was statistically significant (*P < 
0.05) in five cells shown in B, but insignificant in two other cells. Taken with permission from [33]. 
 
 
Figure 4. Properties of adenosine release at cerebellar parallel fibre-Purkinje cell synapses. 
Biosensor recordings were made from transverse cerebellar slices from P21-28 rats.  Biosensors 
were laid on the surface of the molecular layer and adenosine release was evoked with a stimulating 
electrode placed on the same beam of parallel fibres. A) Superimposed current traces from 
adenosine and null biosensors following electrical stimulation (20 Hz, 5 s). The lack of signal on the 
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null sensor indicates the current on the adenosine biosensor is due to purine detection and is not 
non-specific. B) Superimposed traces from an adenosine biosensor placed on the surface of the 
molecular layer and an ATP biosensor placed within the molecular layer (under the adenosine 
sensor).  Following stimulation, although adenosine was measured, no ATP could be detected. C) 
Superimposed current traces from an adenosine biosensor in control, CNQX (10 µM) and AP5 (50 
µM, to block glutamate receptors) and TTX (0.5 µM, to block action potentials). The adenosine 
released by stimulation was blocked by TTX but was insensitive to the block of ionotropic 
glutamate receptors. D) Superimposed current traces from an adenosine biosensor in control and in 
the presence of the mGluR4 receptor agonist L-AP4 (50 µM).  The amount of adenosine released 
following stimulation was reversibly reduced by the activation of mGluR4 receptors. E) 
Superimposed traces from an adenosine biosensor in control and in the presence of the A1 receptor 
antagonist 8CPT (1 µM).  Block of A1 receptors markedly increased the amount of adenosine 
released. F) Current model of adenosine release. Trains of parallel fibre action potentials release 
adenosine (Ado, shaded area) which can diffuse between fibres.  Inset, close-up of parallel fibre-
Purkinje cell synapses (dotted area in A).  Following an action potential train, active fibres release 
adenosine and glutamate.  Adenosine feeds back to inhibit its own release and glutamate release, via 
A1 receptors.  Adenosine may also diffuse to inhibit release from neighbouring inactive fibres 
(lateral inhibition). The release of adenosine is also inhibited by mGlu4R receptor activation (which 
could occur by feedback of released glutamate) and GABAB receptor activation. A-E modified from 
[60]. 
 
 
 
 
 
